Literature DB >> 29158355

Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Ping Yu Xiong1, Francois Potus1, Winnie Chan1, Stephen L Archer2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29158355      PMCID： PMC5777609          DOI： 10.1161/HYPERTENSIONAHA.117.08824

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  161 in total

1.  Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?

Authors:  N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation.

Authors:  Yasuo Ido; David Carling; Neil Ruderman
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

Review 3.  Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH.

Authors:  J Ryan; K Bloch; S L Archer
Journal:  Int J Clin Pract Suppl       Date:  2011-08

4.  Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

Authors:  Thomas F Lüscher; Frank Enseleit; Richard Pacher; Veselin Mitrovic; Matthias R Schulze; Roland Willenbrock; Rainer Dietz; Valentin Rousson; David Hürlimann; Sebastian Philipp; Thomas Notter; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

Review 5.  Guanylate cyclase and the .NO/cGMP signaling pathway.

Authors:  J W Denninger; M A Marletta
Journal:  Biochim Biophys Acta       Date:  1999-05-05

6.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management.

Authors:  D L Moraes; W S Colucci; M M Givertz
Journal:  Circulation       Date:  2000-10-03       Impact factor: 29.690

7.  Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension.

Authors:  Glenn Marsboom; Peter T Toth; John J Ryan; Zhigang Hong; Xichen Wu; Yong-Hu Fang; Thenappan Thenappan; Lin Piao; Hannah J Zhang; Jennifer Pogoriler; Yimei Chen; Erik Morrow; E Kenneth Weir; Jalees Rehman; Stephen L Archer
Journal:  Circ Res       Date:  2012-04-17       Impact factor: 17.367

8.  PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.

Authors:  Anna R Hemnes; Ari Zaiman; Hunter C Champion
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-10-26       Impact factor: 5.464

9.  Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Authors:  Ganesh Raghu; Juergen Behr; Kevin K Brown; Jim J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Steven D Nathan; Athol U Wells; Harold R Collard; Ulrich Costabel; Luca Richeldi; Joao de Andrade; Nasreen Khalil; Lake D Morrison; David J Lederer; Lixin Shao; Xiaoming Li; Patty S Pedersen; A Bruce Montgomery; Jason W Chien; Thomas G O'Riordan
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

10.  Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension.

Authors:  Mark Southwood; Robert V MacKenzie Ross; Rhoda E Kuc; Guy Hagan; Karen K Sheares; David P Jenkins; Martin Goddard; Anthony P Davenport; Joanna Pepke-Zaba
Journal:  Life Sci       Date:  2016-02-10       Impact factor: 5.037
View more
  8 in total

Review 1.  Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?

Authors:  Mélanie Lambert; Véronique Capuano; Andrea Olschewski; Jessica Sabourin; Chandran Nagaraj; Barbara Girerd; Jason Weatherald; Marc Humbert; Fabrice Antigny
Journal:  Int J Mol Sci       Date:  2018-10-14       Impact factor: 5.923

2.  Hypoxia-induced alterations in the lung ubiquitin proteasome system during pulmonary hypertension pathogenesis.

Authors:  Brandy E Wade; Jingru Zhao; Jing Ma; C Michael Hart; Roy L Sutliff
Journal:  Pulm Circ       Date:  2018-06-21       Impact factor: 3.017

Review 3.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

Review 4.  Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?

Authors:  Kondababu Kurakula; Valérie F E D Smolders; Olga Tura-Ceide; J Wouter Jukema; Paul H A Quax; Marie-José Goumans
Journal:  Biomedicines       Date:  2021-01-09

5.  Effect of EZH2 on pulmonary artery smooth muscle cell migration in pulmonary hypertension.

Authors:  Ying Wang; Xiao-Xi Huang; Dong Leng; Ji-Feng Li; Yan Liang; Tao Jiang
Journal:  Mol Med Rep       Date:  2020-12-14       Impact factor: 2.952

6.  Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension.

Authors:  Yuncong Yang; Sirui Zhang; Qian Zhou; Chen Zhang; Yuqi Gao; Hao Wang; Zhe Li; Deyan Wu; Yinuo Wu; Yi-You Huang; Lei Guo; Hai-Bin Luo
Journal:  Acta Pharm Sin B       Date:  2020-04-18       Impact factor: 11.413

7.  Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.

Authors:  Haifeng Jin; Yu Jiao; Linna Guo; Yong Ma; Rongjie Zhao; Xuemei Li; Lei Shen; Zhongguang Zhou; Sang Chan Kim; Jicheng Liu
Journal:  Int J Mol Med       Date:  2020-12-08       Impact factor: 4.101

Review 8.  Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling.

Authors:  Marta T Gomes; Yang Bai; Simone R Potje; Lu Zhang; Angelia D Lockett; Roberto F Machado
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.